VCEL Stock Overview
A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Vericel Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$57.26 |
| 52 Week High | US$57.81 |
| 52 Week Low | US$32.31 |
| Beta | 1.67 |
| 11 Month Change | 39.05% |
| 3 Month Change | 20.55% |
| 1 Year Change | 61.34% |
| 33 Year Change | 42.47% |
| 5 Year Change | 204.57% |
| Change since IPO | -94.89% |
Recent News & Updates
Recent updates
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Nov 09
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
Jul 12Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 11It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Apr 26Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Mar 02Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Feb 02Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
May 05Vericel Corporation: Stock Has Fallen, But Not Enough To Make This A Buy
Oct 10Vericel Q2 2022 Earnings Preview
Aug 02Calculating The Fair Value Of Vericel Corporation (NASDAQ:VCEL)
Apr 19Vericel - A Disruptive Business With Years Of Growth Remaining
Apr 12Vericel: In The Middle Of Difficulty Is An Opportunity
Dec 31Shareholder Returns
| VCEL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | -6.5% | -1.0% |
| 1Y | 61.3% | 14.6% | 30.3% |
Return vs Industry: VCEL exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: VCEL exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| VCEL volatility | |
|---|---|
| VCEL Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VCEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VCEL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 314 | Nick Colangelo | vcel.com |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corporation Fundamentals Summary
| VCEL fundamental statistics | |
|---|---|
| Market cap | US$2.76b |
| Earnings (TTM) | US$3.55m |
| Revenue (TTM) | US$226.84m |
796.6x
P/E Ratio12.5x
P/S RatioIs VCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCEL income statement (TTM) | |
|---|---|
| Revenue | US$226.84m |
| Cost of Revenue | US$64.73m |
| Gross Profit | US$162.12m |
| Other Expenses | US$158.57m |
| Earnings | US$3.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.072 |
| Gross Margin | 71.47% |
| Net Profit Margin | 1.56% |
| Debt/Equity Ratio | 0% |
How did VCEL perform over the long term?
See historical performance and comparison